ClinicalTrials.gg
Active, not recruitingNCT05104476AMULETUpdated Apr 13, 2026Results posted

A Study of Lu AF82422 in Participants With Multiple System Atrophy

A Phase 2 interventional study of Lu AF82422 and Placebo in Multiple System Atrophy, sponsored by H. Lundbeck A/S. Active, not recruiting at 19 sites in 2 countries. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by H. Lundbeck A/S · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 90 studies in Multiple System Atrophy with a site in United States — 21 open to participants now, 32 under way, 1 of them phase 3. Multiple System Atrophy · United States.

Enrollment
21st of 57
64 · median 35
Started
2021
with 6 others
Phase 2
17 of 90
2 open now
Primary completion
2023-11
later than 0 of 31 live
Registered
62nd of 90
by date
Lead sponsor
3 of 90
H. Lundbeck A/S

Among the 90 studies in Multiple System Atrophy with a site in United States, this one is the 21st largest by enrollment of the 57 interventional ones that give a count, is one of 7 that started in 2021, is one of 17 in phase 2, reaches primary completion later than 0 of the 31 other live ones, and was the 62nd registered.

Multiple System Atrophy

207 studies on the registry are indexed under Multiple System Atrophy; 73 are open to participants now.

Browse Multiple System Atrophy studies →

Open to participants now

21 of the 90 studies in Multiple System Atrophy with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 57 Multiple System Atrophy studies recruiting now, 24 (42%) set no upper age limit and 11 (19%) stop at 75 or younger; 7 take children under 18; 18 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies in Multiple System Atrophy with a site in United States, or all of them as a file.
02

Study summary

To find out the effect of Lu AF82422 on disease progression in participants with multiple system atrophy.

Read the detailed description

This study will consist of a double-blind period (DBP) and will include an optional open-label treatment extension (OLE) period. Participants in the DBP will be randomized to Lu AF82422 or placebo (2:1). All participants entering the OLE will receive Lu AF82422 during the OLE.

03

Conditions studied

  • Multiple System Atrophy

Keywords

  • Multiple System Atrophy
  • Neurodegenerative Disorder
  • Autonomic Failure
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • The participant is diagnosed with possible or probable MSA of the multiple system atrophy parkinsonian type (MSA-P) or multiple system atrophy cerebellar type (MSA-C) sub-type at the Screening Visit.
  • The participant had onset of motor and/or autonomic (orthostatic or urinary) MSA symptoms within 5 years prior to the Screening Visit in the judgement of the investigator.
  • The participant has an UMSARS Part I score ≤16 (omitting item 11 on sexual function) at the Screening Visit.
  • The participant has a cognitive performance evaluated by the (MoCA) with a score ≥22 at the Screening Visit.

Open-label Extension Entry Criteria

  • The participant has completed the EoT Visit and did not withdraw in the DBP.
  • The participant has consented to participate in the OLE.
  • The participant has completed the DBP within the last 5 months and will be enrolled into the OLE no later than end of Q1 2024.
  • The participant is, in the Investigator's opinion, likely to comply with the protocol.
  • The participant has not received any other product since the EOoTDBP Visit.

Key Exclusion Criteria:

  • The participant has been treated with an anti-α-synuclein monoclonal antibody, mesenchymal stem cells or an inhibitor of α-synuclein aggregation within the last 12 months.
  • The participant has any past or current treatment with an active vaccine targeting α-synuclein.
  • The participant has 2 or more blood relatives with a history of MSA.
  • The participant has evidence (clinically or on MRI) and/or history of any disease or condition other than MSA (for example, serious neurological disorder, other intracranial disease, or systemic disease).
  • The participant has a current diagnosis of movement disorders that could mimic MSA (for example, Parkinson' disease, dementia with Lewy bodies, essential tremor, progressive supranuclear palsy, spinocerebellar ataxia, spastic paraparesis, corticobasal degeneration, or vascular, pharmacological, or post-encephalitic parkinsonism), per investigator discretion.

Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Lu AF82422

    Participants in the DBP will receive Lu AF82422 intravenous (IV) infusion every 4 weeks (Q4W) from Baseline for a minimum 48 weeks up to a maximum 72 weeks. In the optional OLE, all participants will receive Lu AF82422 IV infusion starting on Day 1 of the OLE up to week 188.

    Drug: Lu AF82422

  • Experimental
    Placebo

    Participants in the DBP will receive Lu AF82422 matching placebo IV infusion Q4W from Baseline for a minimum 48 weeks up to a maximum 72 weeks.

    Drug: Placebo

Interventions

  • Solution for infusion

  • DrugPlacebo

    Solution for infusion

06

What researchers measure

Primary outcomes

  1. Percentage Slowing of Clinical Progression Based on Change From Baseline in the UMSARS TS at the End of Treatment (EOT) DB Period (DBP)

    The primary endpoint assessed disease progression by a Bayesian repeated measures model on UMSARS TS. Reported here is the estimated slowing (%) of clinical progression in participants receiving Lu AF82422 relative to those receiving placebo. UMSARS is a combined clinician and patient-reported outcome assessment developed to provide a surrogate measure of disease progression in multiple system atrophy (MSA). UMSARS TS was obtained by the sum of the items from Part I and Part II. Part I assesses historical information on symptoms and activities of daily living over the past 2 weeks and Part II consists of a clinical examination of key MSA motor signs and symptoms. UMSARS TS score was the sum of all items and ranged from 0 (no impairment) to 104 (severe impairment). A higher score indicated greater impairment.

    Time frame: Baseline up to Week 72

Secondary outcomes

  1. Change From Baseline in the UMSARS TS at the End of Treatment (EOT) DBP

    UMSARS is a combined clinician and patient-reported scale to assess motor impairment in MSA participants. UMSARS TS was obtained by the sum of the items from Part I and Part II. Part I assesses historical information on symptoms and activities of daily living over the past 2 weeks (12 items) rated on a scale ranging from 0 = not affected to 4 = unable to do the activity. Part I total score ranged between 0 to 48 (higher score indicated greater impairment). Part II consists of a clinical examination of key MSA motor signs and symptoms (14 items) rated on a scale ranging from 0 = normal to 4 = marked/severe impairment. Part II total score ranged between 0 and 56 (higher score indicated greater impairment). UMSARS TS score was the sum of all 26 items and ranged from 0 (no impairment) to 104 (severe impairment). A higher score indicated greater impairment. LS mean and SE were calculated using MMRM.

    Time frame: Baseline, Weeks 48 and 72

  2. Change From Baseline in the Modified UMSARS Part I (mUMSARS) Score at the EOT DBP

    UMSARS Part 1 assesses historical information on symptoms and activities of daily living over the past 2 weeks as reported by participants and caregivers (12 items) rated on a scale ranging from 0 to 4; with 0 = not affected/normal 1= mildly affected/impaired, 2= moderately affected/impaired, 3= severely affected/impaired, and 4 = helpless or entirely affected/impaired. The modified UMSARS part I (mUMSARS) score was derived by collapsing the response option 0 and 1 within each item (0 \& 1 =1). Hence, the mUMSARS score ranged from 12 to 48 (higher score indicated greater impairment). LS mean and SE were calculated using MMRM.

    Time frame: Baseline, Weeks 48 and 72

  3. Change From Baseline in the UMSARS Part I Scores at the EOT DBP

    UMSARS Part 1 assesses historical information on symptoms and activities of daily living over the past 2 weeks as reported by participants and caregivers (12 items: speech, swallowing, handwriting, cutting food and handling utensils, dressing, hygiene, walking, falling, orthostatic symptoms, urinary function, sexual function, and bowel function) each rated on a scale ranging from 0 to 4; with 0 = not affected/normal 1= mildly affected/impaired, 2= moderately affected/impaired, 3= severely affected/impaired, and 4 = helpless or entirely affected/impaired. Part I total score ranged between 0 to 48 (higher score indicated greater impairment). LS mean and SE were calculated using MMRM.

    Time frame: Baseline, Weeks 48 and 72

  4. Change From Baseline in the UMSARS Part II Scores at the EOT DBP

    UMSARS Part II consists of a clinical examination of key MSA motor signs and symptoms (14 items: facial expression, speech, ocular motor dysfunction, tremor at rest, action tremor, increased tone, rapid alternating movements of hands, finger taps, leg agility, heel-knee-shin test, arising from chair, posture, body sway, gait) each rated on a scale ranging from 0 to 4; with 0 = not affected/normal 1= mildly affected/impaired, 2= moderately affected/impaired, 3= severely affected/impaired, and 4 = helpless or entirely affected/impaired. Part II total score ranged between 0 and 56 (higher score indicated greater impairment). LS mean and SE were calculated using MMRM.

    Time frame: Baseline, Weeks 48 and 72

  5. Change From Baseline in Schwab and England Activities of Daily Living (SE-ADL) Score at Week 48 in the DBP

    The SE-ADL is a combined participant- and clinician-reported scale to assess participants physical functioning in activities in daily living to grade functional status. For this study, only the clinician-rated part was administered. The SE-ADL scale uses percentages to represent how much effort and dependence on others, participants need to complete daily chores. The SE-ADL scale ranged from 0% indicating worst possible function (fully dependent) to 100% indicating no impairment (completely independent). LS mean and SE were calculated using MMRM.

    Time frame: Baseline, Week 48

  6. Change From Baseline in Clinical Global Impression - Severity of Illness (CGI-S) Score at Week 48 in the DBP

    The CGI-S was administered by an experienced neurologist familiar with MSA participants to make an expert clinical global judgement about the severity of the disease across various time points. The rating was based upon observed and reported symptoms, behaviour, and function in the past seven days. The CGI-S was rated on a scale ranging from 0 to 4 (whereas the 0 = normal, not impaired; 1 = mildly impaired; 2 = moderately impaired; 3 = severely impaired; 4 = extremely impaired). LS mean and SE were calculated using MMRM.

    Time frame: Baseline, Week 48

  7. Change From Baseline in Patient Global Impression - Severity of Illness (PGI-S) Score at Week 48 in the DBP

    The PGI-S is a self-reported single item to evaluate all aspects of participants' MSA symptoms. Participants were asked to choose the response that best described the severity of their MSA symptoms over the past week. The question was rated on a 5-point scale ranging from 0 to 4 (0 = none; 1 = minor; 2 = moderate; 3 = severe; 4 = very severe). LS mean and SE were calculated using MMRM.

    Time frame: Baseline, Week 48

  8. Change From Baseline in Observer-Reported Global Impression - Severity of Illness (OGI-S) Score at Week 48 in the DBP

    The OGI-S is a single-question carer/observer-reported outcome to evaluate all aspects of participants' MSA symptoms. Carer/observers were asked to choose the response that best described the observed severity of MSA symptoms in the person they care for over the past week. The question was rated on a 5-point scale ranging from 0 to 4 (0 = none; 1 = minor; 2 = moderate; 3 = severe; 4 = very severe). LS mean and SE were calculated using MMRM.

    Time frame: Baseline, Week 48

  9. Composite Autonomic Symptom Score Select Change (COMPASS Select Change) Total Score at Week 48 in the DBP

    The COMPASS Select, a participant-reported scale, consists of a subset of 36 items derived from the original COMPASS, to assess severity of autonomic symptoms in MSA during the last year. The COMPASS Select includes 3 domains related to blood pressure control: syncope, orthostatic intolerance, and vasomotor symptoms; and 3 domains focused on symptoms of disturbed secretomotor, bladder, and sleep function. The COMPASS Select Change is a derivate of COMPASS Select, consisting of 16 items in which participants were asked to score their change in autonomic symptoms since their last visit. The scoring algorithm of COMPASS was highly complicated and required computer analysis for score generation. COMPASS Change Select score ranged from -150 to 150. A higher score indicated greater autonomic symptom severity.

    Time frame: Week 48

  10. Change From Baseline in UMSARS Part IV Score at Week 48 in the DBP

    The UMSARS part IV comprised a global disability scale ranging from 1-5, with 1 = 'Completely independent. Able to do all chores with minimal difficulty or impairment. Essentially normal. Unaware of any difficulty'; 2 = 'Not completely independent. Needs help with some chores'; 3 = 'More dependent. Help with half of chores. Spends a large part of the day with chores'; 4 = 'Very dependent. Now and then does a few chores alone or begins alone. Much help needed'; and 5 = 'Totally dependent and helpless. Bedridden'. LS mean and SE were calculated using MMRM.

    Time frame: Baseline, Week 48

  11. Change From Baseline in Speech, Swallowing, Falls, and Walking, as Assessed by the UMSARS Part I Item Scores at Week 48 in the DBP

    UMSARS Part I assesses historical information on symptoms and activities of daily living over the past 2 weeks as reported by participants and caregivers (12 items: speech, swallowing, handwriting, cutting food and handling utensils, dressing, hygiene, walking, falling, orthostatic symptoms, urinary function, sexual function, and bowel function) each rated on a scale ranging from 0 to 4; with 0 = not affected/normal 1= mildly affected/impaired, 2= moderately affected/impaired, 3= severely affected/impaired, and 4 = helpless or entirely affected/impaired. LS mean and SE were calculated using MMRM.

    Time frame: Baseline, Week 48

  12. Change From Baseline in Number of Falls, as Assessed by the Fall Diary Periods (Weeks 44 to 48) in the DBP

    Fall Diary period was defined as the period between the two visits where the diary was filled out according to the protocol. LS mean and SE were calculated using MMRM.

    Time frame: Baseline, Weeks 44 to 48

  13. Change From Baseline in EuroQol 5-Dimension, 5-Level (EQ-5D-5L) Score at Week 48 in the DBP

    The EQ-5D-5L is a participant-reported assessment designed to measure the participant's wellbeing. It consisted of 5 descriptive items (mobility, self-care, usual activities, pain/discomfort, and depression/anxiety) and a visual analogue scale (VAS) of the overall health state. Each descriptive item was rated on a 5-point index ranging from 1 (no problems) to 5 (extreme problems). The VAS ranged from 0 (worst imaginable health state) to 100 (best imaginable health state). LS mean and SE were calculated using MMRM.

    Time frame: Baseline, Week 48

  14. Percent Change From Baseline in Brain Volume With Ventricles, as Measured by Volumetric MRI (vMRI) at Week 48 in the DBP

    LS mean and SE were calculated using MMRM.

    Time frame: Baseline, Week 48

  15. Percent Change From Baseline in P-Neurofilament Light Chain (NfL) Protein Concentration at Week 48 in the DBP

    LS mean and SE were calculated using MMRM.

    Time frame: Baseline, Week 48

  16. Lu AF82422 Plasma Concentration in the DBP

    Time frame: Weeks 0, 4, 6, 8, 12, 24, 36, 48, 60, 72, 88

  17. Lu AF82422 Cerebrospinal Fluid (CSF) Concentrations in the DBP

    Time frame: Weeks 0 and 48

  18. Lu AF82422 CSF/Plasma Concentration Ratio in the DBP

    Time frame: Weeks 0 and 48

07

Results

Posted Dec 27, 2024

Participant flow

This study included a Placebo-controlled Double-blind Period (DBP) (48 weeks up to 72 weeks) and an Optional Open-label Extension (OLE) Period (96 weeks). Individual participant End of Trial (EOT) DBP will vary from 48 to 72 weeks. Once the last participant reaches week 48, the remaining participants will have their next scheduled visit converted to EOT DBP.

Participant flow — Overall Study
MilestonePlaceboLu AF82422
Started2242
Received at least 1 dose of study drug2140
Completed1632
Not completed610
Withdrew: Randomized but not treated12
Withdrew: Adverse event22
Withdrew: Withdrawal by subject33
Withdrew: Other than specified03

Outcome measures

PrimaryPercentage Slowing of Clinical Progression Based on Change From Baseline in the UMSARS TS at the End of Treatment (EOT) DB Period (DBP)

The primary endpoint assessed disease progression by a Bayesian repeated measures model on UMSARS TS. Reported here is the estimated slowing (%) of clinical progression in participants receiving Lu AF82422 relative to those receiving placebo. UMSARS is a combined clinician and patient-reported outcome assessment developed to provide a surrogate measure of disease progression in multiple system atrophy (MSA). UMSARS TS was obtained by the sum of the items from Part I and Part II. Part I assesses historical information on symptoms and activities of daily living over the past 2 weeks and Part II consists of a clinical examination of key MSA motor signs and symptoms. UMSARS TS score was the sum of all items and ranged from 0 (no impairment) to 104 (severe impairment). A higher score indicated greater impairment.

Time frame:
Baseline up to Week 72
Reported as:
Number · Percentage Slowing of Clin. Progression
Percentage Slowing of Clinical Progression Based on Change From Baseline in the UMSARS TS at the End of Treatment (EOT) DB Period (DBP)
Percentage Slowing of Clin. ProgressionLu AF82422 or Placebo
Percentage Slowing of Clinical Progression Based on Change From Baseline in the UMSARS TS at the End of Treatment (EOT) DB Period (DBP)19
Statistical analysis
  • Lu AF82422 or Placebo · Bayesian progression model: 0.81 · 95% CI 0.56 to 1.13Reported here is the estimated effect parameter from the Bayesian Progression Model and the associated Credibility Interval for the active arm.
SecondaryChange From Baseline in the UMSARS TS at the End of Treatment (EOT) DBP

UMSARS is a combined clinician and patient-reported scale to assess motor impairment in MSA participants. UMSARS TS was obtained by the sum of the items from Part I and Part II. Part I assesses historical information on symptoms and activities of daily living over the past 2 weeks (12 items) rated on a scale ranging from 0 = not affected to 4 = unable to do the activity. Part I total score ranged between 0 to 48 (higher score indicated greater impairment). Part II consists of a clinical examination of key MSA motor signs and symptoms (14 items) rated on a scale ranging from 0 = normal to 4 = marked/severe impairment. Part II total score ranged between 0 and 56 (higher score indicated greater impairment). UMSARS TS score was the sum of all 26 items and ranged from 0 (no impairment) to 104 (severe impairment). A higher score indicated greater impairment. LS mean and SE were calculated using MMRM.

Time frame:
Baseline, Weeks 48 and 72
Reported as:
Least squares mean · units on a scale
Change From Baseline in the UMSARS TS at the End of Treatment (EOT) DBP
units on a scalePlaceboLu AF82422
Change at Week 4813.93 ± 3.4213.32 ± 2.86
Change at Week 7219.13 ± 3.7415.10 ± 3.00
SecondaryChange From Baseline in the Modified UMSARS Part I (mUMSARS) Score at the EOT DBP

UMSARS Part 1 assesses historical information on symptoms and activities of daily living over the past 2 weeks as reported by participants and caregivers (12 items) rated on a scale ranging from 0 to 4; with 0 = not affected/normal 1= mildly affected/impaired, 2= moderately affected/impaired, 3= severely affected/impaired, and 4 = helpless or entirely affected/impaired. The modified UMSARS part I (mUMSARS) score was derived by collapsing the response option 0 and 1 within each item (0 \& 1 =1). Hence, the mUMSARS score ranged from 12 to 48 (higher score indicated greater impairment). LS mean and SE were calculated using MMRM.

Time frame:
Baseline, Weeks 48 and 72
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Modified UMSARS Part I (mUMSARS) Score at the EOT DBP
units on a scalePlaceboLu AF82422
Change at Week 487.07 ± 1.626.48 ± 1.33
Change at Week 728.40 ± 2.008.77 ± 1.44
SecondaryChange From Baseline in the UMSARS Part I Scores at the EOT DBP

UMSARS Part 1 assesses historical information on symptoms and activities of daily living over the past 2 weeks as reported by participants and caregivers (12 items: speech, swallowing, handwriting, cutting food and handling utensils, dressing, hygiene, walking, falling, orthostatic symptoms, urinary function, sexual function, and bowel function) each rated on a scale ranging from 0 to 4; with 0 = not affected/normal 1= mildly affected/impaired, 2= moderately affected/impaired, 3= severely affected/impaired, and 4 = helpless or entirely affected/impaired. Part I total score ranged between 0 to 48 (higher score indicated greater impairment). LS mean and SE were calculated using MMRM.

Time frame:
Baseline, Weeks 48 and 72
Reported as:
Least squares mean · units on a scale
Change From Baseline in the UMSARS Part I Scores at the EOT DBP
units on a scalePlaceboLu AF82422
Change at Week 487.64 ± 1.926.98 ± 1.59
Change at Week 728.49 ± 2.2110.23 ± 1.65
SecondaryChange From Baseline in the UMSARS Part II Scores at the EOT DBP

UMSARS Part II consists of a clinical examination of key MSA motor signs and symptoms (14 items: facial expression, speech, ocular motor dysfunction, tremor at rest, action tremor, increased tone, rapid alternating movements of hands, finger taps, leg agility, heel-knee-shin test, arising from chair, posture, body sway, gait) each rated on a scale ranging from 0 to 4; with 0 = not affected/normal 1= mildly affected/impaired, 2= moderately affected/impaired, 3= severely affected/impaired, and 4 = helpless or entirely affected/impaired. Part II total score ranged between 0 and 56 (higher score indicated greater impairment). LS mean and SE were calculated using MMRM.

Time frame:
Baseline, Weeks 48 and 72
Reported as:
Least squares mean · units on a scale
Change From Baseline in the UMSARS Part II Scores at the EOT DBP
units on a scalePlaceboLu AF82422
Change at Week 487.16 ± 2.156.76 ± 1.83
Change at Week 7210.24 ± 2.387.10 ± 1.93
SecondaryChange From Baseline in Schwab and England Activities of Daily Living (SE-ADL) Score at Week 48 in the DBP

The SE-ADL is a combined participant- and clinician-reported scale to assess participants physical functioning in activities in daily living to grade functional status. For this study, only the clinician-rated part was administered. The SE-ADL scale uses percentages to represent how much effort and dependence on others, participants need to complete daily chores. The SE-ADL scale ranged from 0% indicating worst possible function (fully dependent) to 100% indicating no impairment (completely independent). LS mean and SE were calculated using MMRM.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · units on a scale
Change From Baseline in Schwab and England Activities of Daily Living (SE-ADL) Score at Week 48 in the DBP
units on a scalePlaceboLu AF82422
Change From Baseline in Schwab and England Activities of Daily Living (SE-ADL) Score at Week 48 in the DBP-23.56 ± 7.40-20.82 ± 6.52
SecondaryChange From Baseline in Clinical Global Impression - Severity of Illness (CGI-S) Score at Week 48 in the DBP

The CGI-S was administered by an experienced neurologist familiar with MSA participants to make an expert clinical global judgement about the severity of the disease across various time points. The rating was based upon observed and reported symptoms, behaviour, and function in the past seven days. The CGI-S was rated on a scale ranging from 0 to 4 (whereas the 0 = normal, not impaired; 1 = mildly impaired; 2 = moderately impaired; 3 = severely impaired; 4 = extremely impaired). LS mean and SE were calculated using MMRM.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · units on a scale
Change From Baseline in Clinical Global Impression - Severity of Illness (CGI-S) Score at Week 48 in the DBP
units on a scalePlaceboLu AF82422
Change From Baseline in Clinical Global Impression - Severity of Illness (CGI-S) Score at Week 48 in the DBP0.58 ± 0.170.34 ± 0.14
SecondaryChange From Baseline in Patient Global Impression - Severity of Illness (PGI-S) Score at Week 48 in the DBP

The PGI-S is a self-reported single item to evaluate all aspects of participants' MSA symptoms. Participants were asked to choose the response that best described the severity of their MSA symptoms over the past week. The question was rated on a 5-point scale ranging from 0 to 4 (0 = none; 1 = minor; 2 = moderate; 3 = severe; 4 = very severe). LS mean and SE were calculated using MMRM.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · units on a scale
Change From Baseline in Patient Global Impression - Severity of Illness (PGI-S) Score at Week 48 in the DBP
units on a scalePlaceboLu AF82422
Change From Baseline in Patient Global Impression - Severity of Illness (PGI-S) Score at Week 48 in the DBP-0.07 ± 0.210.18 ± 0.18
SecondaryChange From Baseline in Observer-Reported Global Impression - Severity of Illness (OGI-S) Score at Week 48 in the DBP

The OGI-S is a single-question carer/observer-reported outcome to evaluate all aspects of participants' MSA symptoms. Carer/observers were asked to choose the response that best described the observed severity of MSA symptoms in the person they care for over the past week. The question was rated on a 5-point scale ranging from 0 to 4 (0 = none; 1 = minor; 2 = moderate; 3 = severe; 4 = very severe). LS mean and SE were calculated using MMRM.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · units on a scale
Change From Baseline in Observer-Reported Global Impression - Severity of Illness (OGI-S) Score at Week 48 in the DBP
units on a scalePlaceboLu AF82422
Change From Baseline in Observer-Reported Global Impression - Severity of Illness (OGI-S) Score at Week 48 in the DBP0.36 ± 0.220.20 ± 0.18
SecondaryComposite Autonomic Symptom Score Select Change (COMPASS Select Change) Total Score at Week 48 in the DBP

The COMPASS Select, a participant-reported scale, consists of a subset of 36 items derived from the original COMPASS, to assess severity of autonomic symptoms in MSA during the last year. The COMPASS Select includes 3 domains related to blood pressure control: syncope, orthostatic intolerance, and vasomotor symptoms; and 3 domains focused on symptoms of disturbed secretomotor, bladder, and sleep function. The COMPASS Select Change is a derivate of COMPASS Select, consisting of 16 items in which participants were asked to score their change in autonomic symptoms since their last visit. The scoring algorithm of COMPASS was highly complicated and required computer analysis for score generation. COMPASS Change Select score ranged from -150 to 150. A higher score indicated greater autonomic symptom severity.

Time frame:
Week 48
Reported as:
Mean · units on a scale
Composite Autonomic Symptom Score Select Change (COMPASS Select Change) Total Score at Week 48 in the DBP
units on a scalePlaceboLu AF82422
Composite Autonomic Symptom Score Select Change (COMPASS Select Change) Total Score at Week 48 in the DBP18.79 ± 41.9834.28 ± 26.86
SecondaryChange From Baseline in UMSARS Part IV Score at Week 48 in the DBP

The UMSARS part IV comprised a global disability scale ranging from 1-5, with 1 = 'Completely independent. Able to do all chores with minimal difficulty or impairment. Essentially normal. Unaware of any difficulty'; 2 = 'Not completely independent. Needs help with some chores'; 3 = 'More dependent. Help with half of chores. Spends a large part of the day with chores'; 4 = 'Very dependent. Now and then does a few chores alone or begins alone. Much help needed'; and 5 = 'Totally dependent and helpless. Bedridden'. LS mean and SE were calculated using MMRM.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · units on a scale
Change From Baseline in UMSARS Part IV Score at Week 48 in the DBP
units on a scalePlaceboLu AF82422
Change From Baseline in UMSARS Part IV Score at Week 48 in the DBP1.35 ± 0.351.13 ± 0.30
SecondaryChange From Baseline in Speech, Swallowing, Falls, and Walking, as Assessed by the UMSARS Part I Item Scores at Week 48 in the DBP

UMSARS Part I assesses historical information on symptoms and activities of daily living over the past 2 weeks as reported by participants and caregivers (12 items: speech, swallowing, handwriting, cutting food and handling utensils, dressing, hygiene, walking, falling, orthostatic symptoms, urinary function, sexual function, and bowel function) each rated on a scale ranging from 0 to 4; with 0 = not affected/normal 1= mildly affected/impaired, 2= moderately affected/impaired, 3= severely affected/impaired, and 4 = helpless or entirely affected/impaired. LS mean and SE were calculated using MMRM.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · units on a scale
Change From Baseline in Speech, Swallowing, Falls, and Walking, as Assessed by the UMSARS Part I Item Scores at Week 48 in the DBP
units on a scalePlaceboLu AF82422
Speech0.61 ± 0.260.19 ± 0.21
Swallowing0.57 ± 0.300.91 ± 0.25
Falls0.36 ± 0.420.22 ± 0.36
Walking1.02 ± 0.270.86 ± 0.23
SecondaryChange From Baseline in Number of Falls, as Assessed by the Fall Diary Periods (Weeks 44 to 48) in the DBP

Fall Diary period was defined as the period between the two visits where the diary was filled out according to the protocol. LS mean and SE were calculated using MMRM.

Time frame:
Baseline, Weeks 44 to 48
Reported as:
Least squares mean · falls
Change From Baseline in Number of Falls, as Assessed by the Fall Diary Periods (Weeks 44 to 48) in the DBP
fallsPlaceboLu AF82422
Change From Baseline in Number of Falls, as Assessed by the Fall Diary Periods (Weeks 44 to 48) in the DBP-0.18 ± 0.05-0.16 ± 0.04
SecondaryChange From Baseline in EuroQol 5-Dimension, 5-Level (EQ-5D-5L) Score at Week 48 in the DBP

The EQ-5D-5L is a participant-reported assessment designed to measure the participant's wellbeing. It consisted of 5 descriptive items (mobility, self-care, usual activities, pain/discomfort, and depression/anxiety) and a visual analogue scale (VAS) of the overall health state. Each descriptive item was rated on a 5-point index ranging from 1 (no problems) to 5 (extreme problems). The VAS ranged from 0 (worst imaginable health state) to 100 (best imaginable health state). LS mean and SE were calculated using MMRM.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · units on a scale
Change From Baseline in EuroQol 5-Dimension, 5-Level (EQ-5D-5L) Score at Week 48 in the DBP
units on a scalePlaceboLu AF82422
Mobility Score0.75 ± 0.320.49 ± 0.28
Self Care Score0.80 ± 0.380.74 ± 0.32
Usual Activities Score0.50 ± 0.390.87 ± 0.34
Pain/Discomfort Score-0.06 ± 0.380.22 ± 0.33
Anxiety/Depression Score0.05 ± 0.290.34 ± 0.25
VAS Score-13.16 ± 6.46-13.80 ± 5.74
SecondaryPercent Change From Baseline in Brain Volume With Ventricles, as Measured by Volumetric MRI (vMRI) at Week 48 in the DBP

LS mean and SE were calculated using MMRM.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Brain Volume With Ventricles, as Measured by Volumetric MRI (vMRI) at Week 48 in the DBP
percent changePlaceboLu AF82422
Percent Change From Baseline in Brain Volume With Ventricles, as Measured by Volumetric MRI (vMRI) at Week 48 in the DBP-1.14 ± 0.39-0.81 ± 0.33
SecondaryPercent Change From Baseline in P-Neurofilament Light Chain (NfL) Protein Concentration at Week 48 in the DBP

LS mean and SE were calculated using MMRM.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · percent change
Percent Change From Baseline in P-Neurofilament Light Chain (NfL) Protein Concentration at Week 48 in the DBP
percent changePlaceboLu AF82422
Percent Change From Baseline in P-Neurofilament Light Chain (NfL) Protein Concentration at Week 48 in the DBP10.37 ± 11.606.81 ± 10.01
SecondaryLu AF82422 Plasma Concentration in the DBP
Time frame:
Weeks 0, 4, 6, 8, 12, 24, 36, 48, 60, 72, 88
Reported as:
Mean · nanograms (ng)/milliliter (mL)
Lu AF82422 Plasma Concentration in the DBP
nanograms (ng)/milliliter (mL)Lu AF82422
Week 0NA ± NA
Week 4186754 ± 63989
Week 6408806 ± 148195
Week 8285079 ± 170320
Week 12312451 ± 128006
Week 24418385 ± 349787
Week 36417758 ± 170012
Week 48390751 ± 181489
Week 60526706 ± 312743
Week 72544071 ± 355696
Safety Follow Up (Week 88)42425 ± 18372
SecondaryLu AF82422 Cerebrospinal Fluid (CSF) Concentrations in the DBP
Time frame:
Weeks 0 and 48
Reported as:
Mean · ng/mL
Lu AF82422 Cerebrospinal Fluid (CSF) Concentrations in the DBP
ng/mLLu AF82422
Week 05 ± 0
Week 481531 ± 886
SecondaryLu AF82422 CSF/Plasma Concentration Ratio in the DBP
Time frame:
Weeks 0 and 48
Reported as:
Mean · ratio
Lu AF82422 CSF/Plasma Concentration Ratio in the DBP
ratioLu AF82422
Week 025.00 ± 0.00
Week 480.40 ± 0.21

Adverse events

Collected over From date of first dose up to Week 88. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo2/21 (9.5%)7/21 (33.3%)14/21 (66.7%)
Lu AF824222/40 (5%)12/40 (30%)34/40 (85%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventPlaceboLu AF82422
UrosepsisInfections and infestations0/212/40
Cardio-respiratory arrestCardiac disorders1/210/40
COVID-19Infections and infestations1/211/40
SepsisInfections and infestations1/210/40
Urinary tract infectionInfections and infestations1/211/40
FallInjury, poisoning and procedural complications1/211/40
Femoral neck fractureInjury, poisoning and procedural complications1/210/40
Pelvic fractureInjury, poisoning and procedural complications1/210/40
Back painMusculoskeletal and connective tissue disorders1/210/40
Facet joint syndromeMusculoskeletal and connective tissue disorders1/210/40
Most frequent other events
Showing 10 of 29
Most frequent other events
EventPlaceboLu AF82422
COVID-19Infections and infestations5/2110/40
Back painMusculoskeletal and connective tissue disorders2/216/40
HeadacheNervous system disorders1/215/40
Oedema peripheralGeneral disorders1/214/40
Urinary tract infectionInfections and infestations2/214/40
HypertensionVascular disorders0/214/40
Gastrooesophageal reflux diseaseGastrointestinal disorders2/210/40
FatigueGeneral disorders2/213/40
Injection site extravasationGeneral disorders2/211/40
Seasonal allergyImmune system disorders2/210/40

Baseline characteristics

All-patients-treated set (APTS) included all randomized participants who took at least 1 dose of double-blind investigational medicinal product (IMP).

Age, Continuous
Age, Continuous(years)PlaceboLu AF82422Total
Mean59.8 ± 6.8561.4 ± 8.0960.8 ± 7.67
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLu AF82422Total
Female101929
Male112132
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboLu AF82422Total
American Indian or Alaska Native000
Asian51217
Native Hawaiian or Other Pacific Islander000
Black or African American112
White152641
More than one race000
Unknown or Not Reported011
Unified Multiple System Atrophy Rating Scale (UMSARS) Part I and Part II Total Score (UMSARS TS)
Unified Multiple System Atrophy Rating Scale (UMSARS) Part I and Part II Total Score (UMSARS TS)(units on a scale)PlaceboLu AF82422Total
Mean37 ± 7.7734.8 ± 935.5 ± 8.59
08

Study locations

19 sites
09

References and documents

Publications

  • Kjaersgaard L, Wiedemann J, Singer W, Takeda A, Berger AK, Flensburg MF, Hansen L, Kallunki P, Kompus K, Nighah K, Schmidt SN, Jorgensen MN, Svanholm Fogh B, Zanigni S, Luthman J; AMULET Trial Group. Safety and efficacy of the anti-alpha-synuclein monoclonal antibody amlenetug for the treatment of patients with multiple system atrophy (AMULET): a phase 2, randomised, double-blind, multicentre trial. Lancet Neurol. 2026 Jun;25(6):560-570. doi: 10.1016/S1474-4422(26)00100-6. Epub 2026 Apr 24. PubMed 42044642 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Nov 2023, 24 months.

Results were first posted in Dec 2024, 1 year 1 month after primary completion.

Of 19 phase 2 interventional studies under Multiple System Atrophy, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 32. This study's 24 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2021
First posted
Nov 3, 2021
StartActual
Nov 16, 2021
Primary completionActual
Nov 16, 2023
CompletionEst.
Mar 7, 2028
Results first posted
Dec 27, 2024
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05104476
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Nov 3, 2021
Start date
Nov 16, 2021
Primary completion
Nov 16, 2023
Completion
Mar 7, 2028 (estimated)
Results posted
Dec 27, 2024
Last update
Apr 13, 2026

Study contacts

Email contact via H. Lundbeck A/S
study director · H. Lundbeck A/S

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlenetug

Start the discussion